Bristol Myers Squibb (BMY) concluded the recent trading session at $59.62, signifying a +1.39% move from its prior day's close.

By Karen Roman Biopharmaceutical company ReAlta Life Sciences said it appointed Andrew Miller, Ph.D., to its Board of ...

Shares of Bristol Myers Squibb Co. BMY rose 1.39% to $59.62 Friday, on what proved to be an all-around positive trading ...

The brain drug developer is continuing a trial despite a recommendation it be stopped for futility. Elsewhere, Eli Lilly ...

On track to report initial data from Phase 1/2 clinical trial of PM359 for p47phox CGD in 2025 -- -- IND-enabling studies ongoing for PM577 for Wilson's Disease; expect to file IND and/or CTA in ...

On track to report initial data from Phase 1/2 clinical trial of PM359 for p47phox CGD in 2025 ---- IND-enabling studies ongoing for PM577 for ...

Receiving admilparant, an oral lysophosphatidic acid receptor 1 antagonist, for 26 weeks lowered percent-predicted FVC ...

It has been a volatile start to 2025 for growth and technology stocks. While many have raced out to juicy gains, we’ve also ...

Four top stocks have at least a 4% dividend and make sense for investors who may be worried about increased volatility in the ...

After two years in the shadows, health stocks are back as a haven for investors navigating economic uncertainty.

Half of all pancreatic cancer patients live less than a year after diagnosis. But researchers say there is potential for ...